To explore the effect and difference of percutaneous coronary intervention (PCI) and medical therapy on quality of life and cognitive function in patients with coronary heart disease (CHD), and to investigate the relationship between quality of life and cognitive function. Methods: A total of 320 patients with CHD, who underwent coronary angiography and PCI (PCI group, n=160), or underwent coronary angiography and medical therapy (drug therapy group, n=160), were selected. The quality of life was assessed by using the Health Survey Form SF-36 (SF-36) and the Seattle Angina Questionnaire (SAQ), and the cognitive function was assessed by using the Mini-Mental State Examination (MMSE). General data of patients were collected on the day of coronary angiography. Telephone follow-up was conducted in 1 month after treatment, and the outpatient review was carried out in 3 and 6 months after treatment. Results: A total of 309 valid questionnaires were collected. The scores of quality of life in the PCI group and the drug therapy group after treatment were both increased compared with those before treatment (both P<0.05). The SF-36 scores of four dimensions (role physical, bodily pain, vitality and mental health) in the PCI group were all significantly greater than those in the drug therapy group (all P<0.05). The SAQ scores of two dimensions (angina stability and angina frequency) were both higher in the PCI group than those in the drug therapy group in 6 months of post-operation (all P<0.05). There was no significant difference in cognitive function before and after the treatment in the 2 groups (P>0.05). There was no significant difference in cognitive function between the PCI group and the drug therapy group (P>0.05). In the PCI group, physical function, role physical, bodily pain, and role emotional were positively correlated with cognitive function (r=0.207, 0.182, 0.184, 0.176 respectively, all P<0.05). In the drug therapy group, there was no correlation between quality of life and cognitive function. Conclusion: The quality of life for the patients is improved in the PCI group and the drug therapy group, but the improvement degree in the PCI group is more obvious. Both PCI and drug therapy do not result in the decrease of cognitive function, and there is no difference between the 2 groups. There is positive correlation between quality of life and cognitive function in the PCI group, there is no correlation between quality of life and cognitive function in the drug therapy group.
目的：探讨经皮冠状动脉介入(percutaneous coronary intervention，PCI)和药物治疗对冠心病(coronary heart disease，CHD)患者生活质量和认知功能的影响及其区别，以及生活质量与认知功能的关系。方法：从冠状动脉造影患者中选取PCI的CHD患者160例(PCI组)，药物治疗的CHD患者160例(药物治疗组)。采用健康调查表SF-36(Short-form-36 Health Survey)和西雅图心绞痛问卷(Seattle Angina Questionnaire，SAQ)评估患者的生活质量，采用简易智能精神状态检查量表(Mini-Mental State Examination，MMSE)评估患者的认知功能。在完成冠状动脉造影术当天收集患者的一般资料。治疗后1个月进行电话随访，3个月和6个月通知门诊复查。结果：共收回有效问卷309份。PCI组和药物治疗组生活质量评分均比治疗前高(均P<0.05)。PCI组生理职能、躯体疼痛、精力、精神健康这4个维度的SF-36评分均比药物治疗组高(均P<0.05)。术后6个月PCI组心绞痛稳定状态、心绞痛发作频率这2个维度的SAQ评分均比药物治疗组高(均P<0.05)。两组患者治疗前后认知功能差异均无统计学意义(均P>0.05)。两组之间的认知功能差异亦无统计学意义(P>0.05)。PCI组生理机能、生理职能、躯体疼痛、情感智能与认知功能呈正相关关系(分别r=0.207，0.182，0.184，0.176，均P<0.05)，药物治疗组生活质量与认知功能无相关关系。结论：PCI组和药物治疗组患者的生活质量均得到改善，但PCI组改善更明显。PCI和药物治疗均未出现认知功能下降，且两组间无差异。PCI组生活质量与认知功能呈正相关关系，药物治疗组生活质量与认知功能无相关关系。.